GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » SAB Biotherapeutics Inc (NAS:SABS) » Definitions » Cash Flow from Investing

SAB Biotherapeutics (SAB Biotherapeutics) Cash Flow from Investing : $-31.49 Mil (TTM As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is SAB Biotherapeutics Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, SAB Biotherapeutics spent $0.13 Mil on purchasing property, plant, equipment. It gained $0.00 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $31.23 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.00Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, SAB Biotherapeutics spent $31.36 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


SAB Biotherapeutics Cash Flow from Investing Historical Data

The historical data trend for SAB Biotherapeutics's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SAB Biotherapeutics Cash Flow from Investing Chart

SAB Biotherapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
-0.61 -12.72 -10.94 -2.09 -0.15

SAB Biotherapeutics Quarterly Data
Dec19 Jun20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.04 -0.07 -31.36

SAB Biotherapeutics Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

SAB Biotherapeutics's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

SAB Biotherapeutics's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-31.49 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


SAB Biotherapeutics  (NAS:SABS) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

SAB Biotherapeutics's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.13 Mil. It means SAB Biotherapeutics spent $0.13 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

SAB Biotherapeutics's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.00 Mil. It means SAB Biotherapeutics gained $0.00 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

SAB Biotherapeutics's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means SAB Biotherapeutics spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

SAB Biotherapeutics's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means SAB Biotherapeutics gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

SAB Biotherapeutics's purchase of investment for the three months ended in Mar. 2024 was $-31.23 Mil. It means SAB Biotherapeutics spent {stock_data.stock.currency_symbol}}31.23 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

SAB Biotherapeutics's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means SAB Biotherapeutics gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

SAB Biotherapeutics's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $0.00 Mil. It means SAB Biotherapeutics paid $0.00 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

SAB Biotherapeutics's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means SAB Biotherapeutics paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

SAB Biotherapeutics's cash from other investing activities for the three months ended in Mar. 2024 was $0.00 Mil. It means SAB Biotherapeutics paid $0.00 Mil for other investing activities.


SAB Biotherapeutics Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of SAB Biotherapeutics's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


SAB Biotherapeutics (SAB Biotherapeutics) Business Description

Traded in Other Exchanges
N/A
Address
2100 East 54th Street North, Sioux Falls, SD, USA, 57104
SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.
Executives
Eddie Joe Sullivan director, 10 percent owner, officer: Chief Executive Officer 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Michael King officer: CHIEF FINANCIAL OFFICER 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Samuel J Reich director, officer: Executive Chairman ACUITY PHARMACEUTICALS INC, 3701 MARKET STREET, PHILADELPHIA PA 19104
Sessa Capital Im, L.p. director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Andrew Moin director 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Sessa Capital (master), L.p. director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Im Gp, Llc director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
John Petry director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Sessa Capital Gp, Llc director 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10019
Erick Lucera director 138 THISTLE ROAD, NORTH ANDOVER MA 08145
David Charles Link director 2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Christine E Hamilton director, 10 percent owner 225 S MAIN AVE, P O BOX 5000, SIOUX FALLS SD 57117
Scott Giberson director 2100 EAST 54TH STREET NORTH, SIOUX FALLS SD 57104
Alexandra Kropotova officer: Chief Medical Officer RIVER OAKS TOWER, 8800 HSC PARKWAY, BYRAN TX 77807
Jeffrey G Spragens director 4400 BISCAYNE BOULEVARD, SUITE 1500, MIAMI FL 33137

SAB Biotherapeutics (SAB Biotherapeutics) Headlines

From GuruFocus

SAB Biotherapeutics Provides Company Update for Full Year 2022

By sperokesalga sperokesalga 03-31-2023